433 related articles for article (PubMed ID: 27680515)
1. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Fasan A; Haferlach C
Leukemia; 2017 Mar; 31(3):705-711. PubMed ID: 27680515
[TBL] [Abstract][Full Text] [Related]
2. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
[TBL] [Abstract][Full Text] [Related]
6. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
8. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.
Wattel E; Preudhomme C; Hecquet B; Vanrumbeke M; Quesnel B; Dervite I; Morel P; Fenaux P
Blood; 1994 Nov; 84(9):3148-57. PubMed ID: 7949187
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and characteristics of patients with
Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
[TBL] [Abstract][Full Text] [Related]
11. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
[TBL] [Abstract][Full Text] [Related]
12. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
14. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of the clinical and laboratory data from 300 patients of various hematological malignancies with chromosome 3 abnormalities.
Liu D; Zhang Y; Chen S; Pan J; He X; Liang J; Chen Z
Cancer Genet; 2015 Jun; 208(6):333-40. PubMed ID: 26032184
[TBL] [Abstract][Full Text] [Related]
16. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Marvin-Peek J; Mason EF; Kishtagari A; Jayani RV; Dholaria B; Kim TK; Engelhardt BG; Chen H; Strickland S; Savani B; Ferrell B; Kassim A; Savona M; Mohan S; Byrne M
Transplant Cell Ther; 2023 Jun; 29(6):390.e1-390.e10. PubMed ID: 36906277
[TBL] [Abstract][Full Text] [Related]
17. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
18. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
[TBL] [Abstract][Full Text] [Related]
19. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
20. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
